Drug Shortage Report for VIMPAT
| Report ID | 225092 |
| Drug Identification Number | 02357666 |
| Brand name | VIMPAT |
| Common or Proper name | Vimpat IV 10mg/mL |
| Company Name | UCB CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | LACOSAMIDE |
| Strength(s) | 10MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 5 Vials |
| ATC code | N03AX |
| ATC description | ANTIEPILEPTICS |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | 2024-04-15 |
| Actual start date | 2024-04-10 |
| Estimated end date | 2024-04-17 |
| Actual end date | 2024-04-16 |
| Shortage status | Resolved |
| Updated date | 2024-04-17 |
| Company comments | No risk to product integrity, patient safety or patient access. Delay in release due to QA operations change. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2201 BRISTOL CIRCLE OAKVILLE, ONTARIO CANADA L6H 0J8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2024-04-17 | French | Compare |
| v4 | 2024-04-17 | English | Compare |
| v3 | 2024-04-12 | French | Compare |
| v2 | 2024-04-12 | English | Compare |
| v1 | 2024-04-12 | English | Compare |
Showing 1 to 5 of 5